CHEMISTRY CORE The Chemistry Core is the central component of this proposal and will be responsible for engaging in accelerated probe development programs with Specialty Screening and Comprehensive Centers, employing TES and medicinal chemistry design principles in probe development, integrating cheminformatics and computational chemistry into HTS triage and probe design, executing large scale synthesis of probe molecules, developing advanced molecular tools and providing training for TES, parallel synthesis and medicinal chemistry across the MLPCN. The Chemistry Core will work closely with Informatics and Administrative Core to ensure MLPCN goals are met. The following specific aims summarize the major functions of the chemistry core:
AIM 1. To rapidly develop high quality probe molecules employing TES and medicinal chemistry design principles with input from, and analysis with, computational chemistry tools, and to submit all compounds synthesized to the MLSMR on a quarterly basis.
AIM 2. To employ our internal ADME/DMPK component along with in silico methods to further optimize high quality MLPCN probe molecules .
AIM 3. To perform large scale synthesis (>5 g) of probe molecules developed both at Vanderbilt and across the MLPCN and optimize compound formulation.
AIM 4. To collaborate with the Informatics Core for the overlapping responsibility of compound registration and compound management.
AIM 5. To train chemists across the MLPCN in the art of TES and parallel synthesis to accelerate probe development at other Chemistry and Comprehensive Centers.
|Stoll, Kevin; Hart, Rachel; Lindsley, Craig W et al. (2018) Effects of muscarinic M1 and M4 acetylcholine receptor stimulation on extinction and reinstatement of cocaine seeking in male mice, independent of extinction learning. Psychopharmacology (Berl) 235:815-827|
|Gogliotti, Rocco G; Senter, Rebecca K; Fisher, Nicole M et al. (2017) mGlu7 potentiation rescues cognitive, social, and respiratory phenotypes in a mouse model of Rett syndrome. Sci Transl Med 9:|
|Lebois, Evan P; Schroeder, Jason P; Esparza, Thomas J et al. (2017) Disease-Modifying Effects of M1 Muscarinic Acetylcholine Receptor Activation in an Alzheimer's Disease Mouse Model. ACS Chem Neurosci 8:1177-1187|
|Long, Madeline F; Engers, Julie L; Chang, Sichen et al. (2017) Discovery of a novel 2,4-dimethylquinoline-6-carboxamide M4 positive allosteric modulator (PAM) chemotype via scaffold hopping. Bioorg Med Chem Lett 27:4999-5001|
|Bender, Aaron M; Weiner, Rebecca L; Luscombe, Vincent B et al. (2017) Discovery and optimization of 3-(4-aryl/heteroarylsulfonyl)piperazin-1-yl)-6-(piperidin-1-yl)pyridazines as novel, CNS penetrant pan-muscarinic antagonists. Bioorg Med Chem Lett 27:3576-3581|
|Wood, Michael R; Noetzel, Meredith J; Poslusney, Michael S et al. (2017) Challenges in the development of an M4 PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs. Bioorg Med Chem Lett 27:171-175|
|Bender, Aaron M; Weiner, Rebecca L; Luscombe, Vincent B et al. (2017) Synthesis and evaluation of 4,6-disubstituted pyrimidines as CNS penetrant pan-muscarinic antagonists with a novel chemotype. Bioorg Med Chem Lett 27:2479-2483|
|Melancon, Bruce J; Wood, Michael R; Noetzel, Meredith J et al. (2017) Optimization of M4 positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacology. Bioorg Med Chem Lett 27:2296-2301|
|Garcia-Barrantes, Pedro M; Cho, Hyekyung P; Metts, Adam M et al. (2016) Lead optimization of the VU0486321 series of mGlu(1) PAMs. Part 2: SAR of alternative 3-methyl heterocycles and progress towards an in vivo tool. Bioorg Med Chem Lett 26:751-756|
|Wu, Yang; Stauffer, Shaun R; Stanfield, Robyn L et al. (2016) Discovery of Small-Molecule Nonfluorescent Inhibitors of Fluorogen-Fluorogen Activating Protein Binding Pair. J Biomol Screen 21:74-87|
Showing the most recent 10 out of 146 publications